Guardant Health (GH) Stock Rises on Q4 2025 Earnings

Guardant Health (GH) reported fourth-quarter 2025 results.

Revenue: $281.3 million (up 39.4% year-over-year).

Gross profit: $181.8 million (down 7,108.0% year-over-year).

Cost of sales: $99.5 million (up 472.4% year-over-year).

Operating result: operating loss of $120.8 million (down 4.1% year-over-year).

Net income: net loss attributable to common shareholders of $128.5 million (up 2,264.4% year-over-year).

Balance sheet and cash-flow highlights:

Cash used in operating activities: $26.4 million (down 695.6% year-over-year).

Purchases of property, plant and equipment: $27.8 million (up 18,531.2% year-over-year).

Cash and cash equivalents: $378.2 million (down 28.0% year-over-year).

Total liabilities: $2.1 billion (up 30.0% year-over-year).

Estimates and market reaction:

Revenue outperformed the consensus estimate: actual $281.3 million vs. estimate $278.6 million.

Diluted EPS: actual -$1.00 vs. estimate -$0.72.

Stock movement since market close: 3.64%.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Guardant Health Inc. Insider Trading Activity

Guardant Health Inc. insiders have traded $GH stock on the open market 67 times in the past 6 months. Of those trades, 0 have been purchases and 67 have been sales.

Here’s a breakdown of recent trading of $GH stock by insiders over the last 6 months:

HELMY ELTOUKHY (Co-Chief Executive Officer) has made 0 purchases and 4 sales selling 390,565 shares for an estimated $27,238,215.
AMIRALI TALASAZ (Co-Chief Executive Officer) has made 0 purchases and 6 sales selling 100,000 shares for an estimated $10,505,473.
MICHAEL BRIAN BELL (Chief Financial Officer) has made 0 purchases and 12 sales selling 80,362 shares for an estimated $8,288,741.
TERILYN J. MONROE (Chief People Officer) has made 0 purchases and 13 sales selling 73,769 shares for an estimated $7,948,344.
CHRIS FREEMAN (Chief Commercial Officer) has made 0 purchases and 11 sales selling 31,452 shares for an estimated $3,241,621.
IAN T CLARK has made 0 purchases and 3 sales selling 28,611 shares for an estimated $3,066,817.
DARYA CHUDOVA (Chief Technology Officer) has made 0 purchases and 3 sales selling 28,386 shares for an estimated $2,985,111.
JOHN G. SAIA (Chief Legal Officer) sold 8,996 shares for an estimated $865,865
MEDINA MANUEL HIDALGO has made 0 purchases and 5 sales selling 4,915 shares for an estimated $391,280.
KUMUD KALIA (Chief Information Officer) has made 0 purchases and 2 sales selling 4,000 shares for an estimated $332,714.
MUSA TARIQ has made 0 purchases and 4 sales selling 464 shares for an estimated $37,153.
MEGHAN V. JOYCE sold 100 shares for an estimated $6,584
MYRTLE S POTTER has made 0 purchases and 2 sales selling 52 shares for an estimated $3,187.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

Guardant Health Inc. Hedge Fund Activity

We have seen 281 institutional investors add shares of Guardant Health Inc. stock to their portfolio, and 207 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 7,131,895 shares (-78.8%) from their portfolio in Q4 2025, for an estimated $728,451,755
WELLINGTON MANAGEMENT GROUP LLP removed 2,842,566 shares (-87.5%) from their portfolio in Q4 2025, for an estimated $290,339,691
ALLIANCEBERNSTEIN L.P. added 1,761,785 shares (+1262.7%) to their portfolio in Q4 2025, for an estimated $179,948,719
FMR LLC added 1,572,168 shares (+190.7%) to their portfolio in Q4 2025, for an estimated $160,581,239
PRICE T ROWE ASSOCIATES INC /MD/ added 1,414,441 shares (+33.5%) to their portfolio in Q4 2025, for an estimated $144,471,003
POINT72 ASSET MANAGEMENT, L.P. added 1,396,754 shares (+1363.8%) to their portfolio in Q4 2025, for an estimated $142,664,453
DEEP TRACK CAPITAL, LP removed 1,354,086 shares (-32.6%) from their portfolio in Q4 2025, for an estimated $138,306,344

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Guardant Health Inc. Congressional Stock Trading

Members of Congress have traded $GH stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $GH stock by members of Congress over the last 6 months:

SENATOR SHELDON WHITEHOUSE purchased up to $15,000 on 11/21.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

Guardant Health Inc. Analyst Ratings

Wall Street analysts have issued reports on $GH in the last several months. We have seen 15 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Canaccord Genuity issued a "Buy" rating on 12/22/2025
Mizuho issued a "Outperform" rating on 12/17/2025
UBS issued a "Buy" rating on 10/30/2025
Citigroup issued a "Buy" rating on 10/30/2025
Evercore ISI Group issued a "Outperform" rating on 10/30/2025
Barclays issued a "Overweight" rating on 10/30/2025
Piper Sandler issued a "Overweight" rating on 10/22/2025

To track analyst ratings and price targets for Guardant Health Inc., check out Quiver Quantitative's $GH forecast page.

Guardant Health Inc. Price Targets

Multiple analysts have issued price targets for $GH recently. We have seen 17 analysts offer price targets for $GH in the last 6 months, with a median target of $120.0.

Here are some recent targets:

Catherine Schulte from Baird set a target price of $120.0 on 02/17/2026
Subbu Nambi from Guggenheim set a target price of $135.0 on 01/26/2026
Daniel Arias from Stifel set a target price of $120.0 on 01/09/2026
Daniel Markowitz from Evercore ISI Group set a target price of $105.0 on 01/05/2026
Kyle Mikson from Canaccord Genuity set a target price of $125.0 on 12/22/2025
Anthony Petrone from Mizuho set a target price of $120.0 on 12/17/2025
Luke Sergott from Barclays set a target price of $120.0 on 12/15/2025